Trial of daunomycin in acute promyelocytic leukemia of childhood: a Southwest Oncology Group Study.

Abstract

Children with acute promyelocytic leukemia were treated with aggressive daunomycin induction and 6-mercaptopurine and methotrexate maintenance. The remission rate was 8 out of 10 fully evaluable patients. Three are still alive up to 32 months. With vigorous induction therapy, occurrence of disseminated intravascular coagulation was rare. Only one case of DIC was seen in a child who had pseudomonas sepsis at time of diagnosis. Since current protocols are more aggressive, future chemotherapy include patients with acute promyelocytic leukemia.

• Authors: J van Eys, P Steuber, M E Haggard, H Sabio, M Duncan
• Journal: The American journal of pediatric hematology/oncology (Am J Pediatr Hematol Oncol) Vol. 3 Issue 3 Pg. 301-3 ( 1981) ISSN: 0192-8562 [Print] United States
• PMID: 7025685 (Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Daunorubicin

Topics

• Adolescent
• Child
• Child, Preschool
• Clinical Trials as Topic
• Daunorubicin (adverse effects, therapeutic use)
• Disseminated Intravascular Coagulation (chemically induced)
• Humans
• Infant
• Leukemia, Myeloid, Acute (drug therapy)